- Home
- Equipment
- usa new york
- hematologic
Refine by
Hematologic Equipment Supplied In Usa New York
7 equipment items found
Manufactured by:Block Scientific Inc based inBellport, NEW YORK (USA)
CDS 501-003 is comparable to Beckman Coulter Diluent & Reagents Set 8546733. For Use on Coulter S Series, S Plus Series, STKR, MAXM, STKS, GenS, Hmx. 20 Liter ...
Manufactured by:Sight Diagnostics based inBrooklyn, NEW YORK (USA)
Sight’s digital pathology and AI-based hematology platform achieves lab-grade diagnostic accuracy using only two drops of blood. No external reagent management, no maintenance, and no manual calibration required by ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ability to reversibly ...
Manufactured by:CD Formulation based inShirley, NEW YORK (USA)
Bendamustine hydrochloride monotherapy or combination therapy has been designated by European and American clinical guidelines as a first - or second-line treatment option for a variety of hematological ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
In addition to expression on tumor bulk, CD123 expression has been reported on the cancer stem cells (CSCs), of certain hematologic cancers including AML, CML, MDS, and potentially T-cell ALL. In addition, elevated CD123 expression has been correlated with poor prognosis in certain hematologic ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
Inhibition of XPO1 has been shown to restore tumor suppressor function and proper cell cycle regulation, leading to apoptosis of cancer cells. XPO1 has also been shown to be a clinically validated target in both solid and hematological cancers. SL-801 has demonstrated broad and SL-801 has demonstrated broad and potent preclinical activity in a wide array of solid and ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...